Compositions and methods for ameliorating myosin VIIa defects
View Patent ↗The invention provides compositions and methods for ameliorating defects in myosin VIIa (MYO7A) expression and/or function, including providing vectors for myosin VIIa expression and formulations comprising them, and methods of using them, for treating human retinitis pigmentosa (or retinal degeneration), and blindness and deafness such as that found in Usher syndrome. The invention provides in vivo gene therapy for ameliorating defects in myosin VIIa (MYO7A) expression and/or function, including compositions and methods for gene transfer of the human myosin VIIa (MYO7A) gene (the MYO7A gene.
1. A method for the treatment or amelioration of an Usher 1B syndrome ocular disease, comprising delivering subretinally to target cells by injection in at least one eye of a subject in need of said treatment, an expression vehicle comprising or consisting of a human immunodeficiency virus-1 (HIV-1) vector comprising:
(i) a CMV-MYO7A promoter or an equivalent promoter active in a photoreceptor cell and/or a retinal pigment epithelium (RPE) cell in operable linkage with a polynucleotide sequence encoding a myosin VIIA (MYO7A) protein, and
(ii) a chromosomal integration sequence, or a chromosomal integration sequence and a chromatin insulator,
wherein the MYO7A protein is expressed in said target cells, thereby treating the Usher 1B syndrome ocular disease in said subject.
2. The method of claim 1 wherein the promoter comprises a VMD2 promoter.
3. The method of claim 1 , wherein the subject is a human.
4. The method of claim 1 , wherein the MYO7A protein is encoded by a human MYO7A gene.
5. The expression vehicle of claim 4 , wherein the MYO7A protein is encoded by a human MYO7A gene comprising SEQ ID NO:1.
6. A method for treatment or amelioration of blindness due to Usher 1B syndrome in a subject, comprising:
(a) providing an expression vehicle comprising or consisting of a human immunodeficiency virus-1 (HIV-1) vector comprising:
(i) a CMV-MYO7A promoter active in a photoreceptor cell and/or a retinal pigment epithelium (RPE) cell in operable linkage with a polynucleotide sequence encoding a myosin VIIA (MYO7A) protein, and
(ii) a chromosomal integration sequence, or a chromosomal integration sequence and a chromatin insulator,
wherein the MYO7A protein is expressed in a photoreceptor cell or an RPE cell; and
(b) delivering the expression vehicle to the photoreceptor cell or RPE cell in an amount sufficient to express the MYO7A protein in the photoreceptor cell or the RPE cell and thereby treat or ameliorate the Usher 1B syndrome blindness in said subject.
7. The method of claim 6 , wherein the MYO7A protein is encoded by a human MYO7A gene.
8. The expression vehicle of claim 7 , wherein the MYO7A protein is encoded by a human MYO7A gene comprising SEQ ID NO:1.
9. An expression vehicle comprising a human immunodeficiency virus (HIV) vector pseudotyped with the glycoprotein of vesicular stomatitis virus (VSV.G) and comprising a CMV-MYO7A promoter or an equivalent promoter active in a photoreceptor cell and/or a retinal pigment epithelium (RPE) cell in operable linkage with a polynucleotide sequence encoding a myosin VIIA (MYO7A) polypeptide.
10. The expression vehicle of claim 9 , wherein the MYO7A protein is encoded by a human MYO7A gene.
11. The expression vehicle of claim 10 , wherein the MYO7A protein is encoded by a human MYO7A gene comprising SEQ ID NO:1.
12. An ex vivo method for treatment or amelioration of blindness due to Usher 1B syndrome in a subject, comprising:
(a) providing an expression vehicle comprising or consisting of a human immunodeficiency virus-1 (HIV-1) vector comprising:
(i) a CMV-MYO7A promoter active in a photoreceptor cell and/or a retinal pigment epithelium (RPE) cell in operable linkage with a polynucleotide sequence encoding a myosin VIIA (MYO7A) protein, and
(ii) a chromosomal integration sequence, or a chromosomal integration sequence and a chromatin insulator,
wherein the MYO7A protein is expressed in a photoreceptor cell or an RPE cell;
(b) providing the photoreceptor cell and/or the retinal pigment epithelium (RPE) cell;
(c) delivering to the photoreceptor cell and/or the retinal pigment epithelium (RPE) cell the expression vehicle of step (a) in an amount sufficient to express the MYO7A protein in the photoreceptor cell or the RPE cell; and
(d) delivering the photoreceptor cell and/or the retinal pigment epithelium (RPE) cell to an eye subretinally, thereby treating or ameliorating the Usher 1B syndrome in the subject.
13. An expression vehicle comprising an HIV vector pseudotyped with the glycoprotein of vesicular stomatitis virus (VSV.G) vector comprising a CMV-MYO7A active in a photoreceptor cell and/or a retinal pigment epithelium (RPE) cell in operable linkage with a polynucleotide sequence encoding a myosin VIIA (MYO7A) polypeptide.
14. The method of claim 13 , wherein the MYO7A protein is encoded by a human MYO7A gene.
15. A method for the treatment or amelioration of an Usher 1B syndrome ocular disease, comprising delivering subretinally to target cells by injection in at least one eye of a subject in need of said treatment, an expression vehicle comprising or consisting of an HIV vector pseudotyped with the glycoprotein of vesicular stomatitis virus (VSV.G) vector comprising:
(i) a CMV-MYO7A promoter active in a photoreceptor cell and/or a retinal pigment epithelium (RPE) cell in operable linkage with a polynucleotide sequence encoding a myosin VIIA (MYO7A) protein, and
(ii) a chromosomal integration sequence, or a chromosomal integration sequence and a chromatin insulator,
wherein the MYO7A protein is expressed in said target cells, thereby treating the Usher 1B syndrome ocular disease in said subject.
16. The method of claim 15 , wherein the MYO7A protein is encoded by a human MYO7A gene.
17. A method for treatment or amelioration of blindness due to Usher 1B syndrome in a subject, comprising:
(a) providing an expression vehicle comprising or consisting of an HIV vector pseudotyped with the glycoprotein of vesicular stomatitis virus (VSV.G) vector comprising:
(i) a CMV-MYO7A promoter active in a photoreceptor cell and/or a retinal pigment epithelium (RPE) cell in operable linkage with a polynucleotide sequence encoding a myosin VIIA (MYO7A) protein, and
(ii) a chromosomal integration sequence, or a chromosomal integration sequence and a chromatin insulator,
wherein the MYO7A protein is expressed in a photoreceptor cell or an RPE cell; and
(b) delivering the expression vehicle to the photoreceptor cell or RPE cell in an amount sufficient to express the MYO7A protein in the subretinally photoreceptor cell or the RPE cell and thereby treat or ameliorate the Usher 1B syndrome blindness in said subject.
18. The method of claim 17 , wherein the MYO7A protein is encoded by a human MYO7A gene.
19. An ex vivo method for treatment or amelioration of blindness due to Usher 1B syndrome in a subject, comprising:
(a) providing an expression vehicle comprising or consisting of an HIV vector pseudotyped with the glycoprotein of vesicular stomatitis virus (VSV.G) vector comprising:
(i) a CMV-MYO7A promoter active in a photoreceptor cell and/or a retinal pigment epithelium (RPE) cell in operable linkage with a polynucleotide sequence encoding a myosin VIIA (MYO7A) protein, and
(ii) a chromosomal integration sequence, or a chromosomal integration sequence and a chromatin insulator,
wherein the MYO7A protein is expressed in a photoreceptor cell or an RPE cell;
(b) providing the photoreceptor cell and/or the retinal pigment epithelium (RPE) cell;
(c) delivering to the photoreceptor cell and/or the retinal pigment epithelium (RPE) cell the expression vehicle of step (a) in an amount sufficient to express the MYO7A protein in the photoreceptor cell or the RPE cell; and
(d) delivering the photoreceptor cell and/or the retinal pigment epithelium (RPE) cell to an eye subretinally, thereby treating or ameliorating the Usher 1B syndrome in the subject.
20. The method of claim 19 , wherein the MYO7A protein is encoded by a human MYO7A gene.